|
advertisement
|
Company Overview: |
The Durect Corporation is biotechnology company that develops pharmaceutical products based on its exclusive proprietary drug delivery technology platforms. The company’s pharmaceutical systems technologies are applied in various chronic and as well as intermittent disease areas, including pain, central nervous system, disorders, cardiovascular disease, and other chronic diseases.
The Durect Corporation employs a dedicated team of scientists and formulators that offer additional expertise to custom-tailor drug delivery to specific client needs, whether parenteral, oral, transdermal, local or topical. It is this experience and expertise that accelerate product development timelines, reduce overall risk and increase clients’ chances for success.
|
Products and Services: |
Durect Corporation has an impressive list of products included in its present pipeline that are based upon the company’s proprietary drug delivery technology platforms.
Technology Platforms
Durect offers a broad range of innovative drug delivery systems that are an essential element to any new controlled-release drug product. The company offers sustained release technology platforms that provide delivery of products from days to months based on specified therapeutic and business needs.
Durect Corporation’s drug delivery technology platforms include:
SABER Delivery System - An intravenous system created to deliver protein-based and small molecule-based therapeutics.
ORADUR - An orally-administered, sustained release gel-cap technology
TRANSDUR Delivery System - Durect’s proprietary transdermal patch technology
DURIN Biodegradable Implant - A biodegradable drug-loaded implant that delivers a specified through absorption into the body
DUROS System - Durect proprietary osmotic implant technology
MICRODUR Biodegradable Microparticulates - A microsphere injection-based drug delivery system
Products
SABER-Bupivacaine - A Phase 2 drug candidate being developed as treatment for post operative pain
TRANSDUR-Sufentanil - A Phase 2 drug candidate being developed as treatment for chronic pain
Remoxy - Durect’s Phase 3 chronic pain treatment drug
Memryte -A Phase 3 drug candidate that is being developed as a treatment for Alzheimer’s disease
CHRONOGESIC -Another of Durect’s drug candidates still under development for the treatment of chronic pain
The company also offers various other products which are preclinical stage are used for central nervous system disorders and cardiovascular disorders.
The Durect Corporation also manufactures and sells osmotic pumps that are used for animal research, as well as various biodegradable polymers that are utilized by pharmaceutical and medical device clients as a raw material or base ingredients in their products candidates.
ALZET - is a miniature, implantable osmotic pump that is used for experimental research that involves animal testing. The ALZET pumps provide a continuous delivery system for drugs, hormones and other test agents at controlled rates from one day to four weeks without the need for external connections, frequent handling or repeated dosing.
LACTEL - are biodegradable polymers that are derived from glycolide, lactide, and caprolactone monomers and used in medical applications.
|
Key Personnel Facts: |
Felix Theeuwes: Chairman and Chief Scientific Officer
James E. Brown: President, Chief Executive Officer, and Director
Matthew J. Hogan: Chief Financial Officer
Peter J. Langecker: Chief Medical Officer
Jean I. Liu: Senior Vice President and General Counsel
Paula Mendenhall: Senior Vice President of Operations
Su IL Yum: Senior Vice President, Pharmaceutical Systems R&D and Principal Engineer
Nacer E. Dean Abrouk: Vice President, Biostatistics
Harry Guy: Vice President, Engineering and Safety
Schond L. Greenway: Vice President, Investor Relations and Strategic Planning
Jian Li: Vice President, Finance and Corporate Controller
Thomas P. McCracken: Vice President and Chief Patent Counsel
Andrew R. Miksztal: Vice President, Pharmaceutical Research and Development
Charlotte R. Rogers: Vice President, Business Development
Employees (2005): 1381-Year Employee Growth: 4.5%
|
Key Financial Facts: |
Fiscal Year-End: December
Sales (2005): $28.6M
1-Year Sales Growth: 106.3%
Net Income (2005): ($18.1M)
|
Back to Top
|
Jobs @ Durect
View all the jobs @ Durect
Back to Top |
Working @ Durect
Have your shout about working or interveiwing at Durect
1 message posted
Message Posted:
Working @ Durect Corporation
Share your experiences about working, interviewing or applying for a job at Durect ...
Author: Obi Posted: 3/6/2007 12:11:21 PM |
View or add comments about Durect
Back to Top
|
Durect in the News
- DURECT Reports Positive Results from POSIDUR(TM) Phase IIb Hernia Trial, Triggering $8 million ...
Published: Tuesday, July 17, 2007
- Press Release: DURECT Corporation Reports Positive Results from POSIDUR Phase IIb Hernia Trial
Published: Tuesday, July 17, 2007
- Durect gains $8M on positive pain drug data
Published: Tuesday, July 17, 2007
- Corium to Supply Durect with its Post-Shingles Pain Candidate
Published: Monday, February 05, 2007
- DURECT to Present Preliminary Phase II Clinical Data for Cohort 3 for Its Post-Operative Pain Relief Depot at American College of Surgeons Conference
Published: Wednesday, September 21, 2005
View more news about Durect
Back To Top |
|
|
|
|
Categories:
|
Biotechnology
|
|
Back to Top
|
|
|
|